Beam Therapeutics is trading 4% down at $25.75 after investors focused on safety findings in updated BEAM-302 Phase 1/2 data.
- Efficacy appeared durable, but data showed infusion-related reactions and transient liver-enzyme elevations, including one Grade 3 case.
- The stock declined 9.54% on September 8; contemporaneous coverage identified safety as the main reason, while the official release made no explicit market attribution.
- Major U.S. indexes are lower and oil is above $100, potentially adding pressure.